Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.49 |
| ▸ | NOD1 | Q9Y239 | 3/20 | 0.49 |
| ▸ | TLR2 | O60603 | 1/20 | 0.48 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.45 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.43 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.43 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.43 |
| ▸ | NMT2 | O60551 | 1/20 | 0.42 |
| ▸ | NMT1 | P30419 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20099252 | 0.92 | NMT2 (0.49) | GLP1RNOD1TLR2LPAR3EPHX2 | |
| SCHEMBL16217754 | 0.89 | GLP1R (0.48) | GLP1RNOD1TLR2LPAR3LPAR1 | |
| SCHEMBL16250320 | 0.89 | TLR2 (0.52) | GLP1RNOD1TLR2LPAR3LPAR1 | |
| SCHEMBL21893795 | 0.88 | GLP1R (0.49) | GLP1RNOD1TLR2LPAR3LPAR1 | |
| SCHEMBL18879491 | 0.87 | GLP1R (0.49) | GLP1RNOD1TLR2LPAR3LPAR1 | |
| SCHEMBL20099362 | 0.86 | NMT2 (0.53) | GLP1RNOD1TLR2LPAR3LPAR1 | |
| SCHEMBL24383354 | 0.86 | NOD1 (0.54) | GLP1RNOD1TLR2LPAR3LPAR1 | |
| SCHEMBL24119975 | 0.85 | NMT2 (0.46) | GLP1RNOD1TLR2LPAR3LPAR1 | |
| SCHEMBL18879488 | 0.85 | TLR2 (0.48) | GLP1RNOD1TLR2LPAR3LPAR1 | |
| SCHEMBL16217963 | 0.84 | NOD1 (0.42) | GLP1RNOD1TLR2EPHX2SIRT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015179693-A1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | ISIS PHARMACEUTICALS, INC. (US) | 2015-11-26 | — | — | WO | disclosed |
| WO-2014179627-A2 | COMPOSITIONS AND METHODS FOR MODULATING HBV AND TTR EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2014-11-06 | — | — | WO | disclosed |